Last reviewed · How we verify
RC118
At a glance
| Generic name | RC118 |
|---|---|
| Also known as | RC118 for injection |
| Sponsor | RemeGen Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors (PHASE1, PHASE2)
- A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors (PHASE1, PHASE2)
- A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (PHASE1)
- MPN-RC 118 AVID200 in Myelofibrosis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RC118 CI brief — competitive landscape report
- RC118 updates RSS · CI watch RSS
- RemeGen Co., Ltd. portfolio CI